Equities researchers at WBB Securities assumed coverage on shares of Cytosorbents Corp (OTCMKTS:CTSO) in a research report issued on Wednesday. The firm set a “speculative buy” rating and a $13.00 price target on the stock.
A friend pass this along to me.-Please share your comments.
"I'm not sure if you are aware the emerging knowledge that most sepsis patients actually die from a lack of cytokines or immune paralysis, which then triggers activation of latent viral pathogens that contribute to overwhelm the immune response.
* FMC sees forex-adjusted net income growth of 0-5 pct in 2015
* Says foray into new services could weigh on 2015 profit
* Analysts had expected 2015 gain of more than 12 pct -poll
* FMC sees net income growth of 15-20 pct next year
* Shares among top DAX gainers (Adds analyst comment, share price)
FRANKFURT, Feb 25 (Reuters) - Kidney dialysis specialist Fresenius Medical Care forecast strong profit growth in 2016 after more modest progress this year while it cuts costs to counter pressures on payments for treatment in the United States and moves into new healthcare services.
FMC, which operates more than a third of the dialysis treatment centres in the United States, on Wednesday said net income would stagnate or grow by up to 5 percent in 2015 but would increase by 15-20 percent next year, based on current exchange rates.
Analysts had on average hoped for net income growth of more than 12 percent this year and their expectations for an annual dividend of about 0.90 euros were also ahead of FMC's proposed payout of 0.78 euros per share.
But FMC's 2016 guidance beat consensus expectations which had pointed to 14 percent profit growth on average. FMC's shares rose and were among the top gainers on Germany's blue-chip index in mid-morning trade.
"The 2015 guidance did have the potential to create a repeat performance of last year's disappointments, but the fact that management has provided encouraging 2016 guidance should reassure investors that FMC is capable of delivering the kind of growth they expect of it over the long term," Berenberg analysts said in a note to clients.
By 1001 GMT, FMC shares were up 1.8 percent at 66.65 euros, while the DAX was 0.1 percent lower.
INVESTING IN SERVICES
U.S. state-run insurer Medicare has changed the way it pays for medical services, giving clinic operators a financial incentive to reduce costs and use fewer drugs. Medicare no longer pays for the individual services and drugs provided in dialysis but instead makes a lump-sum payment.
The programme is part of a trend in U.S. medical insurance towards making a fixed-rate payment to cover the cost of handling a chronically ill patient.
As a result, FMC has bought up a number of healthcare services companies, seeking to offer bundled treatments for kidney and cardiovascular disease to Medicare and private-sector insurers, saying it can give high-level care at lower costs.
FMC's fourth-quarter net income of $335 million, down 4 percent, was broadly in line with analyst expectations.
FMC's parent, healthcare group Fresenius SE said separately it expected its net income to rise between 9 and 12 percent at constant currencies this year, helped by additional earnings from the purchase of new hospitals and demand for healthcare services.
Fresenius's Kabi business, which makes generic infusion drugs and tube-feeding equipment, is to cut annual costs by about 40 million euros from 2018, with related one-off charges dragging pretax profit 100 million euro lower in 2015.
Hospira, one of Kabi's largest rivals, is being bought by Pfizer for about $15 billion, which could open up new marketing channels for Hospira, especially outside the United States.
2010 Feb;92(2):390-6. doi: 10.1002/jbm.b.31527
Sepsis is characterized by a systemic inflammatory response caused by infection, and can result in organ failure and death. Removal of inflammatory mediators such as cytokines from the circulating blood is a promising treatment for severe sepsis. We are developing an extracorporeal hemoadsorption device to remove cytokines from the blood using biocompatible, polymer sorbent beads. In this study, we used confocal laser scanning microscopy (CLSM) to directly examine adsorption dynamics of a cytokine (IL-6) within hemoadsorption beads. Fluorescently labeled IL-6 was incubated with sorbent particles, and CLSM was used to quantify spatial adsorption profiles of IL-6 within the sorbent matrix. IL-6 adsorption was limited to the outer 15 microm of the sorbent particle over a relevant clinical time period, and intraparticle adsorption dynamics was modeled using classical adsorption/diffusion mechanisms. A single model parameter, alpha = q(max) K/D, was estimated by fitting CLSM intensity profiles to our mathematical model, where q(max) and K are Langmuir adsorption isotherm parameters, and D is the effective diffusion coefficient of IL-6 within the sorbent matrix. Given the large diameter of our sorbent beads (450 microm), less than 20% of available sorbent surface area participates in cytokine adsorption. Development of smaller beads may accelerate cytokine adsorption by maximizing available surface area per bead mass.
Tuesday What’s Hot : Plantronics, Inc. (PLT), Cytosorbents Corporation (CTSO), F.N.B. Corporation (FNB), On Deck Capital, Inc. (ONDK), Umpqua Holdings Corporation (UMPQ)
Cytosorbents Corporation (CTSO) of the Medical Laboratories & Research sector closed out the day Monday at $10.76, a gain of 8.14% and return on investment of 33.30% trading at a volume of 250,287 shares. Cytosorbents Corporation (CTSO) is performing above average with a weekly performance of 31.22% moving into this week with a quarterly performance of and a 52 week low of 144.55%. Cytosorbents Corporation (CTSO)’s monthly performance sits at 31.70%. Cytosorbents Corporation (CTSO) is a good stock in the Medical Laboratories & Research industry with analyst rating of 1.8
Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials
While statins are indicated to reduce blood cholesterol levels, they also have anti--inflammatory and immunomodulatory effects. Several observational cohort studies suggested that statins may improve survival and reduce complications in patients with sepsis. Recent randomized controlled studies in critically ill patients have been conducted and published. In this paper we present a meta--analysis of these randomized trials.
An electronic article search through Pubmed was performed. Only randomized controlled trials including critically ill adult patients with severe sepsis were retained. A meta--analysis was performed as detailed in text below.
Overall analysis including 1818 patients total from 4 studies showed that there was no difference in 60--day mortality between statins ( 223/903 ) and placebo ( 233/899 ) [risk ratio, 0 .930; 95% CI, 0.722 t o 1.198 ]. Similarly, no difference in 28--day mortality was observed between groups (statins 191/907, placebo 199/911; risk ratio 0.953; 95% CI, 0.715 to 1.271 ).
The results of this meta--analysis confirm that the use of statin therapy should not be recommended in the management of severe sepsis in critically ill patients. Statins should be continued with caution and only if necessary, as one study reported that the statin group had a higher rate of hepatic and renal failure
ExThera Medical Corporation has developed its Seraph™ (Selective Removal by Apheresis) platform that consists of heparin coated, solid polyethylene beads. Heparin has the ability to bind some, but not all viruses, bacteria, toxins and cytokines. In in vitro studies using 1 mL of human septic blood, there was no statistically different change in IL-6 or Interferon-gamma compared to control, but effected a ~50% reduction in TNF-alpha. This inability to remove a broad range of cytokines will likely limit its efficacy as a treatment in sepsis. It has repositioned Seraph™ as a pathogen removal technology, and plans to conduct a human trial in Germany in the future. In addition, it has partnered with BioBridge Global to apply its technology to pathogen reduction in transfused blood products.
Case Report: Influenza
Treatment day 1 2 3 4 5 6 7
8,076 1,025 527 172 117 120 107
IL-6 (after) pg/mL 2,621 663 289 76 110 111 94
IL-6 (% change) -68% -35% -45% -56% -6% -8% -12%
-2 -1 0 1 3 2 4 5 6 7 8 10 11 9
Patient was alive and well at 60-day follow-up
56 year old man with documented swine (H1N1) influenza with multiple organ failure.
Interferon levels were undetectable
Entered into an initial partnership with a top-four global medical
device company in cardiac surgery to use CytoSorb
intra-operatively during cardiac surgery in France
• Initial evaluation phase expected to be complete in Q2 2015
• Following a successful evaluation, the two parties plan to jointly
determine how to potentially expand upon both the size and
geographic footprint of its partnership
• France is the second largest medical device market and one of the highest volume
cardiac surgery markets in the EU
• Medtronic, Sorin, Maquet and Terumo are top firms in the cardiac surgery space
If there had already given the mini-ICU, he might be still alive.
Short-term acquisition of several organ functions
So far, there is the system only at the Hospital of the Ludwig-Maximilians-University in Munich. There, a team of experts ready to perform the transport of seriously ill patients. Most recently, she brought a German patients from Kuwait into German Heart Institute Berlin - Flying time: seven hours. In addition to a heart-lung therapy, the patient also needed a kidney replacement. For installed Born a hemofilter, which takes over the renal function. The liver can be relieved with the system: A Cytosorb filter filtered pollutants such as interleukins and cytokines from the blood. "With the mini heart-lung machine comes to the clinic patients as Sabine H., who would otherwise have been celebrated her last Christmas," says Born.
Intensive care unit in miniature
By Andrea Bannert
Many lives can be saved only in a special clinic. For patients who require a heart-lung machine, transportation is the biggest hurdle. A new, portable apparatus is to change the
At the Christmas party is Sabine H. * suddenly bad. When she goes home, the 37-year-old must pass gets severe pain in the chest. The diagnosis of the emergency physician: Cardiogenic shock - the heart does not pump properly. "The fact that I got over that, I owe this unit," she says, pointing to a shoebox large apparatus from a bunch of projects hoses. The apparatus is a heart-lung machine in miniature. The ICU go first presented at the Munich University Hospital.
The device takes over the functions of the heart and lungs . It sucks the blood from the body, it is enriched with oxygen and pumps it back into the arteries. Up to six liters per minute moves the helpers.
Such machines are not new. But usually they take as much space as a high chest of drawers. They are used in the clinic everyday to perform operations on non-beating heart in which the heart and lungs must be eliminated. Your task will then take 70 pound behemoth. It is difficult to carry in an ambulance - Helicopter that is because of the large weight even impossible.
Has developed the heart-lung machine in miniature bioengineer Frank Born. It weighs only ten kilograms, - which also creates each helicopter. "With this system, patients who were previously not fit to be transferred to specialized clinics," said Born. And that can save lives.
Tragic death sentence
Triggered the idea with the portable Lifesaver was a tragic experience: Seven years ago, a young athlete with serious heart problems, was admitted to the hospital, in the Born was working. Actually, the patient should have moved quickly to a specialized center. But because his heart was working only with the support of a heart-lung machine, which was not possible. The 34-year-old died.
CytoSorbents Corporation currently has 4 patents in Australia associated with it. The earliest filing date for these patents is 1/04/2011 and the latest is 10/08/2012. The specific patents currently associated with this applicant are:
Patent Number Title Type Status Filing Date
AU2012295350 Polymeric sorbent for removal of impurities from whole blood and blood products Standard FILED 2012-08-10
AU2012204277 Compositions and methods useful in selectively modifying the internal and external surfaces of porous polymer beads Standard FILED 2012-01-06
AU2012204271 Polymeric sorbent for removal of impurities from whole blood and blood products Standard FILED 2012-01-06
AU2011234978 Method of treating inflammation Standard FILED 2011-04-01